Andre Rodrigues Duraes
Universidade Estadual da Bahia, Brazil
Title: Dabigatran versus Warfarin after bioprosthesis valve replacement for the management of a trial fibrillation postoperatively: A randomized Pilot Study (DAWA)
Biography
Biography: Andre Rodrigues Duraes
Abstract
Context: Warfarin and similar vitamin-K antagonists have been the standard therapy for patients with a metallic valve or bioprosthesis with atrial fibrillation. Even with the appropriate use of therapy, there is a high incidence of thromboembolic events: 1-4% per year. Furthermore, bleeding risk is significant ranging from 2% to 9% per year. Objective: To examine the effect of dabigatran etexilate versus dose-adjusted warfarin for the prevention of intra-cardiac thrombus in persistent or permanent atrial fibrillation (AF) after at least 3 months after aortic and/or mitral bioprosthesis replacement. Design, Setting and Participants: DAWA is a phase-2, prospective, open-label, randomized, pilot trial designed to compare 110 mg twice-daily oral dabigatran etexilate with dose-adjusted warfarin for the prevention of stroke (ischemic or hemorrhagic) and systemic embolism in persistent or permanent atrial fibrillation after bioprosthesis replacement (through research of intra-cardiac thrombus). From August 2013 to April 2015, 100 patients at least 3 months after aortic and/or mitral bioprosthesis replacement and AF postoperatively, who match eligibility criteria will be selected from Ana Nery Hospital in Salvador-Bahia with follow-up of three months.